Nonprofit · EIN 46-3405526
RARE CANCER RESEARCH FOUNDATION
Tax-exempt · DURHAM, NC 27701
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $446,172 | $1,742,257 | -$1,296,085 | $1,358,604 | $338,838 | $1,019,766 |
| December 31, 2024 | 990 | $1,773,373 | $2,240,471 | -$467,098 | $3,059,554 | $743,703 | $2,315,851 |
| December 31, 2023 | 990 | $3,503,960 | $2,167,619 | $1,336,341 | $3,033,890 | $942,133 | $2,091,757 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $175,430
- Program service revenue
- $230,925
- Investment income
- $39,817
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $5,550
- Compensation of officers, directors and key employees
- $642,795
- Other salaries and wages
- $363,737
- Salaries, compensation and benefits (total)
- $1,143,340
- Professional fundraising fees
- $0
- Accounting fees
- $41,460
- Travel
- $40,374
- Depreciation
- $2,368
- Program services (functional)
- $1,351,198
- Management and general (functional)
- $256,958
- Fundraising (functional)
- $134,101
Balance sheet and other
- Total assets, start of year
- $3,059,554
- Total assets, end of year
- $1,358,604
- Total liabilities, end of year
- $338,838
- Net assets, end of year
- $1,019,766
- Net assets without donor restrictions
- $605,406
- Net assets with donor restrictions
- $414,360
- Gross receipts
- $446,172
- Employees
- 9
- Year formed
- 2013
- State of legal domicile
- NC
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARSHALL THOMPSON | CTO Officer | 40 | $176,310 | $5,400 |
| ROBIN KAGEYAMA | DIR DATA PLA Key employee | 40 | $170,143 | $5,388 |
| AMBER SMITH | DIR BIOBANKI Key employee | 40 | $150,001 | $12 |
| BENJAMIN KAMPHAUS | DATA ENGINEE Highest-paid employee | 40 | $133,595 | $5,400 |
| HANA LITTLEFORD | CLINICAL DAT Highest-paid employee | 40 | $120,192 | $5,400 |
| BARBARA VAN HARE | PRES. OF PAT Trustee or director, Officer | 40 | $117,742 | $300 |
| CHRISTINE SPENCER | HEAD OF PRIS Highest-paid employee | 40 | $104,545 | $8 |
| VIRGINIA SPITZER | CEO Officer | 40 | $17,500 | $1 |
| RISHI BAGRODIA | DIRECTOR Trustee or director | 1 | $0 | $0 |
| KEITH LAABS | DIRECTOR Trustee or director | 1 | $0 | $0 |
| CHRIS HEERY MD | CHAIRMAN Trustee or director | 5 | $0 | $0 |
| RYAN PRIPSTEIN | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JANE WILKINSON | DIRECTOR Trustee or director | 1 | $0 | $0 |
990 for the year ended December 31, 2024: 11 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARSHALL THOMPSON | PRESIDENT Officer | 40 | $189,510 | $5,393 |
| ROBIN KAGEYAMA | DIR DATA PLA Key employee | 40 | $162,277 | $5,388 |
| AMBER SMITH | BIOBANK MANA Highest-paid employee | 40 | $150,000 | $12 |
| SUSAN HORRELL | DIR STRATEGI Highest-paid employee | 40 | $139,166 | $5,400 |
| KATHRYN KAY COLEMAN | PROD ENGINEE Highest-paid employee | 40 | $130,977 | $5,187 |
| BARBARA VAN HARE | PRES. OF PAT Trustee or director, Officer | 40 | $119,409 | $300 |
| BENJAMIN DAVID KAMPHAUS | TECHNICAL FE Highest-paid employee | 40 | $102,597 | $4,050 |
| HANA LITTLEFORD | CLINICAL DAT Officer | 40 | $97,702 | $4,500 |
| CHRIS HEERY | CHAIRMAN Trustee or director | 1 | $0 | $0 |
| KEITH LAABS | DIRECTOR Trustee or director | 1 | $0 | $0 |
| RYAN PRIPSTEIN | DIRECTOR Trustee or director | 1 | $0 | $0 |
990 for the year ended December 31, 2023: 6 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| MARSHALL THOMPSON | PRESIDENT Trustee or director, Officer | 40 | $189,251 | $5,175 |
| AMBER SMITH | BIOBANK MANA Highest-paid employee | 40 | $136,717 | $5,175 |
| BARBARA VAN HARE | PRES. OF PAT Trustee or director, Officer | 40 | $121,264 | $5,400 |
| CHRIS HEERY | DIRECTOR Trustee or director, Officer | 1 | $0 | $0 |
| MARK LAABS | FOUNDER & CH Trustee or director, Officer | 15 | $0 | $0 |
| RYAN PRIPSTEIN | DIRECTOR Trustee or director, Officer | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 703 FOSTER ST, DURHAM, NC 27701-2110
- Mailing address (990-N for 2013)
- 272 Wakefield Dr, Memphis TN 38117
- Principal officer (990 for 2025)
- MARSHALL THOMPSON, 703 FOSTER ST, DURHAM, NC 27701
- Principal officer (990-N for 2013)
- Mark J Laabs, 272 Wakefield Dr, Memphis TN 38117
- Signed the 990
- MARSHALL THOMPSON, CTO
- Phone
- (844) 434-7272
- Website
- http://www.rcrf.org
- Return prepared by
- LANGDON & COMPANY LLP
Mission
THE RARE CANCER RESEARCH FOUNDATION IS DEDICATED TO CURING RARE CANCERS THROUGH STRATEGIC INVESTMENTS AND COLLABORATIONS THAT CATALYZE EFFECTIVE RESEARCH AND ACCELERATE DEPLOYMENT OF PROMISING THERAPIES.
Program accomplishments
- PRISM (H37) - A PROGRAM TO CREATE EXCEPTIONAL OUTCOMES FOR INDIVIDUALS FACING ADVANCED CANCERS BY PUSHING THE BOUNDARIES OF SCIENCE, RESEARCH, AND CLINICAL INNOVATIONS. THE FOUNDATION WORKS IN DEEP PARTNERSHIPS WITH A SMALL GROUP OF CLIENTS, EXPLORING THE DETAILED MOLECULAR AND CLINICAL CHARACTERISTICS OF THE INDIVIDUAL CLIENTS DISEASE TO HELP THEM AND THEIR CLINICAL TEAM TO MAKE MORE DATA INFORMED DECISIONS ABOUT THEIR TREATMENT JOURNEY AND CONTRIBUTE THAT DETAILED RESEARCH INFORMATION TO THE DATA PLATFORM FOR FUTURE STUDY.Expenses $347,544 · grants $5,550 · revenue $116,779
- PATTERN.ORG A GROUNDBREAKING ONLINE PLATFORM THAT EMPOWERS CANCER PATIENTS TO CONSENT AND DONATE LIVING TISSUE AND CLINICAL DATA TO RESEARCH REGARDLESS OF THEIR TREATMENT LOCATION IN THE UNITED STATES. ONCE A PATIENT ENROLLS, THE PATTERN.ORG TEAM COORDINATES THE COLLECTION AND SHIPMENT OF THE TISSUE AND DATA TO WORLD CLASS RESEARCH STUDIES WHICH IN TURN BROADLY SHARE ANY RESULTING MODELS AND LEARNING.Expenses $344,230 · revenue $114,146
- DATA PLATFORM A PROGRAM INITIATED IN 2023 TO DEVELOP A UNIFIED PLATFORM TO HOST COMBINED MOLECULAR AND CLINICAL RARE CANCER DATA OBTAINED INTERNALLY AND EXTERNALLY, WHICH WILL BE SHARED BROADLY WITH THE CANCER RESEARCH COMMUNITY.Expenses $404,190
- BIOBANK A PROGRAM THAT MAINTAINS A HIGH-QUALITY REPOSITORY OF CANCER BIOSPECIMENS (TISSUE AND BLOOD), COLLECTED USING STANDARDIZED BEST PRACTICES AND LINKED TO CLINICAL AND MOLECULAR DATA. THE PATTERN BIOBANK SUPPORTS BOTH PATIENTS AND RESEARCH PARTNERS BY PROVIDING CUSTODIAL SERVICES, MANAGING END-TO-END LOGISTICS, AND ACCEPTING DONATED RARE CANCER SAMPLES, PRESERVING AND DISTRIBUTING WELL-CHARACTERIZED SPECIMENS TO ADVANCE RESEARCH AND ACCELERATE DISCOVERY.Expenses $255,234
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 46-3405526
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2014
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H30)
- Assets (IRS master file)
- $1,358,604
- Income (IRS master file)
- $446,172
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | $446,172 | $1,742,257 | $1,358,604 | XML |
| 990 | December 2024 | $1,773,373 | $2,240,471 | $3,059,554 | XML |
| 990 | December 2023 | $3,503,960 | $2,167,619 | $3,033,890 | XML |
| 990 | December 2022 | $37,638 | $333,801 | $757,505 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2018 | – | – | – | IRS |
| 990-N for 2013 Officer: Mark J Laabs | December 31, 2013 | ≤ $50,000 receipts | – | – | e-Postcard |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 46-3405526).
Questions about RARE CANCER RESEARCH FOUNDATION
- What is the EIN of RARE CANCER RESEARCH FOUNDATION?
- The employer identification number (EIN) of RARE CANCER RESEARCH FOUNDATION is 46-3405526.
- Is RARE CANCER RESEARCH FOUNDATION tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2014.
- Are donations to RARE CANCER RESEARCH FOUNDATION tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does RARE CANCER RESEARCH FOUNDATION file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of RARE CANCER RESEARCH FOUNDATION due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did RARE CANCER RESEARCH FOUNDATION last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of RARE CANCER RESEARCH FOUNDATION?
- The 990 for the year ended December 31, 2025 names MARSHALL THOMPSON.
- Who are the officers and directors of RARE CANCER RESEARCH FOUNDATION?
- The 990 for the year ended December 31, 2025 lists 13 people; 8 received compensation from the organization, the highest $176,310 (MARSHALL THOMPSON, CTO).
- How much revenue does RARE CANCER RESEARCH FOUNDATION have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $446,172, expenses of $1,742,257 and total assets of $1,358,604 at year end.
Other nonprofits in DURHAM
- CHORDOMA FOUNDATION EIN 20-8423943 · last filed 990 for 2025
- GLIOBLASTOMA FOUNDATION INC EIN 81-2849764 · last filed 990 for 2024
- SOCIETY FOR TRANSLATIONAL ONCOLOGY INC EIN 20-3186261 · last filed 990 for 2025
- DUKE MEDICINE GLOBAL SUPPORT CORP EIN 61-1593721 · last filed 990 for 2025
- VOA FOUNDATION EIN 88-1907540 · last filed 990-EZ for 2025
- INTERNATIONAL CANCER CARE & RESEARCH EXCELLENCE FOUNDATION INC EIN 47-3821684 · last filed 990-EZ for 2025
- WPLAB INC EIN 86-1413357 · last filed 990 for 2025
- CHAMP FOUNDATION EIN 47-5555752 · last filed 990 for 2024
All nonprofits in DURHAM · North Carolina · Medical research